Jemperli + Zejula combination significantly improved PFS in primary advanced or recurrent endometrial cancer in RUBY Part 2 Ph 3 trial January 4, 2024
FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer January 4, 2024
FAILED TRIAL: Ph 3 LEAP-001 Trial of KEYTRUDA + LENVIMA as 1L Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma did not meet primary dual endpoints December 11, 2023
New Preliminary OS data in Selinexor-Treated Patients with Advanced or Recurrent TP53 WT Endometrial Cancer from the SIENDO Study Announced December 4, 2023
Ph 3 RUBY trial of Jemperli + chemotherapy meets OS endpoint in patients with primary advanced or recurrent endometrial cancer November 7, 2023
Positive CHMP opinion recommending approval of Jemperli (dostarlimab) + chemo as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer October 25, 2023
Jemperli (dostarlimab) + chemo approved in the US as 1L treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer August 9, 2023
Supplemental BLA accepted for priority review for Jemperli + chemo For The Treatment of dMMR/MSI-H Primary Advanced Or Recurrent Endometrial Cancer June 14, 2023
IMFINZI + LYNPARZA and IMFINZI alone both significantly improved PFS in advanced endometrial cancer when added to chemotherapy May 31, 2023
EMA Validates MAA for Jemperli (dostarlimab) + Chemo for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer May 10, 2023
Interim results from Part 1 of Ph 3 RUBY trial of Jemperli + chemo in adult patients with primary advanced or recurrent endometrial cancer announced April 6, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced/Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status April 6, 2023
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01; DisTinGuish Trial of DKN-01 + tislelizumab & chemo to continue as a clinical collaboration March 31, 2023
KEYTRUDA + Chemo Significantly Improved PFS vs chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of MMR Status March 31, 2023
Clinical Responses from the Ph 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer highlighted February 22, 2023
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer February 22, 2023
NRG-GY018 Study Demonstrates Significantly Improved PFS Outcomes for Women with Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy February 8, 2023
KEYTRUDA + Chemo Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma February 8, 2023
Foundation Medicine Announces Collaboration with Karyopharm Therapeutics to Develop FoundationOne®CDx as a Companion Diagnostic for XPOVIO® (selinexor) January 17, 2023
Jemperli (Dostarlimab-Gxly) RUBY Ph 3 Trial Met Its Primary Endpoint In A Planned Interim Analysis In Patients With Primary Advanced Or Recurrent Endometrial Cancer December 5, 2022
